Search Result

Results for "

NS5A inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (1) Cyclophilin (1) DNA/RNA Synthesis (1) Drug Metabolite (2) Endogenous Metabolite (1) HCV (51) HCV Protease (15) Influenza Virus (1) Isotope-Labeled Compounds (8) Reference Standards (5) SARS-CoV (8)
By Research Areas:	Cancer (6) Infection (59) Inflammation/Immunology (8)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15602

Ledipasvir 30+ Cited Publications GS-5885	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.62 μM .

HY-12530

Velpatasvir 5+ Cited Publications GS-5816	HCV SARS-CoV	Infection Inflammation/Immunology Cancer
Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-15789

Elbasvir 5+ Cited Publications MK-8742	HCV	Infection
Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC₅₀s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

HY-10466

Daclatasvir Maximum Cited Publications 47 Publications Verification BMS-790052; EBP 883	HCV	Infection
Daclatasvir (BMS-790052) is a potent and orally active *HCV NS5A* protein** inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 µM and 3.27 µM, respectively .

HY-10465

Daclatasvir dihydrochloride Maximum Cited Publications 47 Publications Verification BMS-790052 dihydrochloride; EBP 883 dihydrochloride	HCV	Infection
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active *HCV NS5A* protein** inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

HY-101662

Pibrentasvir ABT-530	HCV	Infection
Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) *NS5A* inhibitor with EC₅₀s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.

HY-13997

Ombitasvir 5+ Cited Publications ABT-267	HCV	Infection
Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC₅₀s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.

HY-15602B

Ledipasvir D-tartrate 30+ Cited Publications GS-5885 D-tartrate	HCV	Infection
Ledipasvir D-tartrate is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-15602A

Ledipasvir (acetone) 30+ Cited Publications GS-5885 (acetone)	HCV	Infection
Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-N1341

Roseoside	HCV HCV Protease DNA/RNA Synthesis Bacterial	Infection
Roseoside is an inhibitor of DNA gyrase and HAV 3C protease, and also inhibits *HCV NS5A/B replicase* in human systems with an IC₅₀ of 20 μM. Roseoside binds to the active site of enzymes and stabilizes the interaction by forming hydrogen bonds with key amino acid residues. Roseoside inhibits the growth of Gram-positive bacteria, Gram-negative bacteria, and Candida albicans, and interferes with HCV RNA replication in vitro by inhibiting *HCV NS5A/B replicase* (IC₅₀=20 μM). Roseoside shows no cytotoxicity and serves as a research tool for studies related to bacterial infections, candidiasis, HAV and HCV .

HY-124191

Ravidasvir hydrochloride PPI-668 hydrochloride	HCV	Infection
Ravidasvir hydrochloride (PPI-668 hydrochloride) is a pan-genotypic inhibitor for hepatitis C virus (HCV) NS5A protein. Ravidasvir hydrochloride inhibits the replication of HCV, with EC₅₀ of 0.12, 0.01 and 1.14 nM, for HCV gt-1a, gt-1b, and gt-3a replicons, respectively. Ravidasvir hydrochloride exhibits good pharmacokinetic characters in rats .

HY-101663

Ruzasvir MK-8408	HCV	Infection
Ruzasvir (MK-8408) is an orally active inhibitor for genotypic HCV nonstructural protein 5A (NS5A), which inhibits the replication of NS5A mutants GT1a, GT1a L31V, GT1a Y93H, GT2b, GT3a and GT4a with EC₉₀ ranging from 0.003 to 0.067 nM. Ruzasvir exhibits good pharmacokinetic characters in rhesus monkey model .

HY-147358

Yimitasvir diphosphate Emitasvir diphosphate; DAG-181 diphosphate	HCV	Infection
Yimitasvir diphosphate (Emitasvir diphosphate; DAG-181 diphosphate) is an orally active inhibitor of hepatitis C virus (HCV) nonstructural protein 5A (NS5A). Yimitasvir diphosphate is applicable to research related to HCV infection .

HY-117411A

Coblopasvir dihydrochloride KW-136 dihydrochloride	HCV HCV Protease	Infection
Coblopasvir (KW-136) dihydrochloride is a pangenotypic non-structural protein 5A *(NS5A)* inhibitor. Coblopasvir dihydrochloride can be used for research of chronic hepatitis C virus infection .

HY-16784

Samatasvir 1 Publications Verification IDX719; IDX18719	HCV HCV Protease	Infection
Samatasvir (IDX71) is a potent, orally active *NS5A* inhibitor of HCV replication. Samatasvir is effective and selective against infectious HCV and replicons, with EC₅₀s falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons .

HY-15602C

Ledipasvir hydrochloride GS-5885 hydrochloride	HCV SARS-CoV	Infection
Ledipasvir (GS-5885) hydrochloride is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir hydrochloride is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.62 μM .

HY-12530R

Velpatasvir (Standard) GS-5816 (Standard)	Reference Standards HCV SARS-CoV	Infection Inflammation/Immunology Cancer
Velpatasvir (Standard) is the analytical standard of Velpatasvir. This product is intended for research and analytical applications. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-10465R

Daclatasvir dihydrochloride (Standard) BMS-790052 dihydrochloride (Standard); EBP 883 dihydrochloride (Standard)	Reference Standards HCV	Infection
Daclatasvir (dihydrochloride) (Standard) is the analytical standard of Daclatasvir (dihydrochloride). This product is intended for research and analytical applications. Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active *HCV NS5A* protein** inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 µM and 3.27 µM, respectively .

HY-N8188

Dehydrojuncusol	HCV HCV Protease	Infection
Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC₅₀=1.35?μM) .

HY-124182

Odalasvir ACH-3102; JNJ64289901	HCV	Infection
Odalasvir (ACH-3102) is a potent and selective inhibitor of HCV NS5A, and can be used in research on hepatitis C virus infection .

HY-147358A

Yimitasvir Emitasvir; DAG-181	HCV	Infection
Yimitasvir (Emitasvir; DAG-181) is an orally active inhibitor of hepatitis C virus (HCV) nonstructural protein 5A (NS5A). Yimitasvir is applicable to research related to HCV infection .

HY-15602D

Ledipasvir (diacetone) GS-5885 (diacetone)	HCV	Infection
Ledipasvir diacetone (GS-5885 diacetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-15602AS

Ledipasvir-d6 hydrochloride GS-5885-d6 hydrochloride	HCV Isotope-Labeled Compounds	Infection
Ledipasvir-d₆ hydrochloride is deuterated labeled Ledipasvir acetone (HY-15602A). Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-P0162

HCV-IN-4	HCV	Infection
HCV-IN-4 is a potent and orally active HCV NS5A inhibitor, shows great potency against GT1a, GT2b, GT3a, GT1a Y93H and GT1a L31V, with EC₉₀s of 3 pM, 0.3 nM, 0.01 nM, 0.5 nM and 0.02 nM, respectively .

HY-123808

MK-8325	HCV	Infection
MK-8325 (Compound 1) is an orally active HCV NS5A inhibitor. MK-8325 exhibits minimal inhibitory activity against hERG at a concentration of 30 mM. MK-8325 may be used in hepatitis C research .

HY-133247

Daclatasvir Impurity B	Drug Metabolite	Others
Daclatasvir Impurity B is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .

HY-168987

Netanasvir	HCV HCV Protease	Infection Inflammation/Immunology
Netanasvir, a *NS5A* inhibitor, possesses antiviral activity. Netanasvir can be used in the study for HCV study .

HY-111087

AZD-7295	HCV Protease	Infection Inflammation/Immunology
AZD-7295 is a HCV NS5A protein inhibitor, with an EC₅₀ of 7 nM for GT-1b replicon .

HY-117411

Coblopasvir KW-136	HCV HCV Protease	Infection Inflammation/Immunology
Coblopasvir (KW-136) is a pangenotypic non-structural protein 5A *(NS5A)* inhibitor. Coblopasvir can be used for research of chronic hepatitis C virus infection .

HY-15789R

Elbasvir (Standard) MK-8742 (Standard)	Reference Standards HCV	Infection
Elbasvir (Standard) is the analytical standard of Elbasvir. This product is intended for research and analytical applications. Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC₅₀s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

HY-15602S

Ledipasvir-d6 GS-5885-d₆	HCV SARS-CoV	Infection
Ledipasvir-d₆ is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.62 μM .

HY-12530S1

Velpatasvir-d3 GS-5816-d3₃	Isotope-Labeled Compounds SARS-CoV HCV	Infection Inflammation/Immunology Cancer
Velpatasvir-d₃ (GS-5816-d₃) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-12373

AV-4025 hydrochloride	HCV Protease Influenza Virus	Infection
AV-4025 hydrochloride (Compound 13a) is an orally active *NS5A* inhibitor. AV-4025 hydrochloride is active against the HCV replicon GT1b (EC₅₀ = 0.003 nM). AV-4025 hydrochloride can be used for research on hepatitis C infection .

HY-145375

NS5A-IN-1	HCV Protease	Infection
NS5A-IN-1 is a proagent of the HCV NS5A inhibitor Pibrentasvir (ABT-530).

HY-115982

NS5A-IN-3	HCV Protease	Infection
NS5A-IN-3 (Compound 15) is a potent inhibitor of *NS5A. NS5A-IN-3 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability. NS5A-IN-3 exhibits a higher resistance barrier than daclatasvir against genotype 1b . NS5A*-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-115981

NS5A-IN-2	HCV Protease	Infection
NS5A-IN-2 (Compound 33) is a potent inhibitor of *NS5A. NS5A-IN-2 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability . NS5A*-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-123649

MK-4882	HCV	Others
MK-4882 is an HCV NS5A inhibitor with activity in reducing viral load in a chimpanzee model of HCV infection, but with issues of viral breakthrough, prompting the development of compounds with greater potency against more genotypes and NS5A resistance mutations.

HY-145335

GSK2818713	HCV Protease	Infection
GSK2818713 is a novel Hepatitis C *NS5A* replication complex inhibitor.

HY-133248

Daclatasvir Impurity C	Drug Metabolite	Others
Daclatasvir Impurity C is the impurity of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .

HY-117967

MK-6169	HCV Protease	Infection
MK-6169 is a potent, pan-genotypic hepatitis C virus *NS5A* inhibitor .

HY-146126

NS5A-IN-4	HCV Protease	Infection
NS5A-IN-4 (Compound 1.12) is an orally active pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with IC₅₀ values of 1.2, 2296, 4.6, 362, 10.3 and 693 pM against gT1b, gT1a, gT2a, gT3a, gT4a and gT5a . NS5A-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-120713

MK-8325 dihydrochloride	HCV	Infection
MK-8325 (dihydrochloride) is an inhibitor of HCV NS5A with oral activity. MK-8325 exhibits minimal inhibition on hERG at the concentration of 30 mM .

HY-133246

Monodes(N-carboxymethyl)valine Daclatasvir Daclatasvir Impurity A	HCV	Infection
Monodes(N-carboxymethyl)valine Daclatasvir (Daclatasvir Impurity A) is the main degradation product of Daclatasvir. Daclatasvir is a potent HCV NS5A protein inhibitor .

HY-136267

HCV-IN-30	HCV	Infection
HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC₅₀s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively .

HY-147358C

(1R,4S)-Yimitasvir diphosphate (1R,4S)-Emitasvir diphosphate; (1R,4S)-DAG-181 diphosphate	HCV	Infection
Yimitasvir (Emitasvir) diphosphate is an orally active hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor and can be used for research of chronic hepatitis C virus infection .

HY-13997R

Ombitasvir (Standard) ABT-267 (Standard)	HCV Reference Standards	Infection
Ombitasvir (Standard) is the analytical standard of Ombitasvir. This product is intended for research and analytical applications. Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.

HY-133246A

Monodes(N-carboxymethyl)valine Daclatasvir TFA Daclatasvir Impurity A TFA	HCV	Infection
Monodes(N-carboxymethyl)valine Daclatasvir TFA (Daclatasvir Impurity A TFA) is the TFA salt form of Monodes(N-carboxymethyl)valine Daclatasvir (HY-133246). Monodes(N-carboxymethyl)valine Daclatasvir TFA is the main degradation product of Daclatasvir (HY-10466). Daclatasvir is a potent HCV NS5A protein inhibitor .

HY-133018

HCV-IN-7	HCV	Infection
HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC₅₀s of 3-47 pM. HCV-IN-7 shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 has anti-viral activity .

HY-133018A

HCV-IN-7 hydrochloride	HCV	Cancer
HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC₅₀s of 3-47 pM. HCV-IN-7 hydrochloride shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 hydrochloride has anti-viral activity .

HY-15602S1

Ledipasvir-d16 GS-5885-d₁₆	Isotope-Labeled Compounds HCV SARS-CoV	Infection
Ledipasvir-d₁₆ (GS-5885-d₁₆) is deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.62 μM .

Cat. No.	Product Name	Target	Research Area

HY-P0162

HCV-IN-4	HCV	Infection
HCV-IN-4 is a potent and orally active HCV NS5A inhibitor, shows great potency against GT1a, GT2b, GT3a, GT1a Y93H and GT1a L31V, with EC₉₀s of 3 pM, 0.3 nM, 0.01 nM, 0.5 nM and 0.02 nM, respectively .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N8188

Dehydrojuncusol	Infection other families Classification of Application Fields Phenols Polyphenols Plants Disease Research Fields Source Classification	HCV HCV Protease
Dehydrojuncusol, a potent HCV inhibitor, targets HCV NS5A and is able to inhibit RNA replication of replicons harboring resistance mutations to anti-NS5A direct-acting antivirals. Dehydrojuncusol significantly inhibits HCV infection when added after virus inoculation of HCV genotype 2a (EC₅₀=1.35?μM) .

Cat. No.	Product Name	Chemical Structure

HY-15602AS

Ledipasvir-d6 hydrochloride
Ledipasvir-d₆ hydrochloride is deuterated labeled Ledipasvir acetone (HY-15602A). Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC₅₀ values of 34 pM against GT1a and 4 pM against GT1b replicon.

HY-15602S

Ledipasvir-d6
Ledipasvir-d₆ is the deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.62 μM .

HY-12530S1

Velpatasvir-d3
Velpatasvir-d₃ (GS-5816-d₃) is deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-15602S1

Ledipasvir-d16
Ledipasvir-d₁₆ (GS-5885-d₁₆) is deuterium labeled Ledipasvir. Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC₅₀s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.62 μM .

HY-10466S

Daclatasvir-d6
Daclatasvir-d₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

HY-10466S2

Daclatasvir-d16
Daclatasvir-d₁₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

HY-W749691

(S)-Velpatasvir-13c,d3
(S)-Velpatasvir- ¹³C,d₃ ((S)-GS-5816- ¹³C,d₃) is ¹³C labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM ^.

HY-12530S3

Velpatasvir-13C,d3
Velpatasvir- ¹³C,d₃ (GS-5816- ¹³C,d₃) is ¹³C and deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 2.16 μM .

HY-10466S1

Daclatasvir-13C2,d6

Daclatasvir- ¹³C2,d₆ (BMS-790052- ¹³C2,d₆) is ¹³C and deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks